EverSource Wealth Advisors
LCTX icon

EverSource Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

EverSource Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-288
Closed -$487 – 4356
2025
Q3 		$487 Sell
288
-714
-71% -$845 ﹤0.01% 3958
2025
Q2 		$909 Buy
1,002
+891
+803% +$529 ﹤0.01% 3761
2025
Q1 		$50 Buy
+111
New +$65 ﹤0.01% 3901

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EverSource Wealth Advisors's LCTX Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 288 shares — an estimated $487 sold.

EverSource Wealth Advisors first reported a position in LCTX in Q1 2025 and held it in 3 quarters. The position peaked at $909 in Q2 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 288 Lineage Cell Therapeutics shares in Q4 2025, an estimated $487.
  • EverSource Wealth Advisors first reported a position in Lineage Cell Therapeutics in Q1 2025 and held it in 3 quarters.
  • EverSource Wealth Advisors's Lineage Cell Therapeutics position peaked at $909 in Q2 2025.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.